TABLE 106Comparison of model results with assumptions from Roche model

ModelADA–DMARDsETN–DMARDsIFX–DMARDsRTX–DMARDsABT–DMARDs
BRAM reference34,30038,90036,10021,10038,400
Changing HAQ increase31,90033,50032,00017,20041,500
Changing short-term withdrawal rate23,80025,10027,40020,50026,400
Changing both24,50024,40026,90017,90030,900
Rochea14,60018,00016,2005,30021,500
a

Results for comparisons not involving RTX are inferred from total costs and QALYs reported by Roche (Tables 101105, p. 226–8 of the company submission).

Results for comparisons not involving RTX are inferred from total costs and QALYs reported by Roche (Tables 101105, p. 226–8 of the company submission).

From: 4, Assessment of cost-effectiveness

Cover of Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a Tumour Necrosis Factor Inhibitor: A Systematic Review and Economic Evaluation
Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a Tumour Necrosis Factor Inhibitor: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.14.
Malottki K, Barton P, Tsourapas A, et al.
Southampton (UK): NIHR Journals Library; 2011 Mar.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.